State Street’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

State Street’s Portfolio CELGZ Stock Details CELGZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-19,361	Closed	-$57K	–	3864
2015 Q1	$57K	Hold	19,361	–	–	﹤0.01%	3576
2014 Q4	$61K	Hold	19,361	–	–	﹤0.01%	3570
2014 Q3	$67K	Hold	19,361	–	–	﹤0.01%	3546
2014 Q2	$50K	Sell	19,361 -20	-0.1%	-$55	﹤0.01%	3544
2014 Q1	$54K	Hold	19,381	–	–	﹤0.01%	3550
2013 Q4	$53K	Sell	19,381 -537	-3%	-$1.51K	﹤0.01%	3533
2013 Q3	$161K	Hold	19,918	–	–	﹤0.01%	3441
2013 Q2	$149K	Buy	+19,918	New	+$144K	﹤0.01%	3364

Other funds holding CELGZ

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

State Street's CELGZ Position: Q2 2015 in Review

State Street sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q2 2015, closing a stake of 19,361 shares — an estimated $57K sold.

State Street first reported a position in CELGZ in Q2 2013 and held it in 8 quarters. The position peaked at $161K in Q3 2013. 23 funds tracked by Wall St. Rank hold CELGZ as of Q2 2015.

State Street reported no remaining Celgene Corporation Contingent Value Rights position as of Q2 2015 after selling out during the quarter.
State Street sold 19,361 Celgene Corporation Contingent Value Rights shares in Q2 2015, an estimated $57K.
State Street first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 8 quarters.
State Street's Celgene Corporation Contingent Value Rights position peaked at $161K in Q3 2013.
23 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q2 2015.

Based on State Street's 13F filing for Q2 2015, filed 13 Aug 2015.